Ricin vaccine - Soligenix

Drug Profile

Ricin vaccine - Soligenix

Alternative Names: Ricin toxin vaccine - Soligenix; RiVax

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer Soligenix
  • Class Subunit vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ricin poisoning
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Ricin poisoning

Most Recent Events

  • 08 Dec 2016 Soligenix receives grant from National Institute of Allergy and Infectious Diseases (NIAID) and Biomedical Advanced Research and Development Authority (BARDA) for ricin vaccine development
  • 13 Feb 2015 Pharmacodynamics and adverse events data from a preclinical study released by Soligenix
  • 02 Sep 2014 Interim pharmacodynamics data from a preclinical trial released by Soligenix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top